2022
DOI: 10.1016/j.molmed.2022.07.006
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 16 publications
(8 citation statements)
references
References 118 publications
0
8
0
Order By: Relevance
“…However, it's important to emphasize that our healthy cohort samples were collected from a different demographic location (Italy) than the patient cohort (Denmark). Although, prior studies have shown comparable vaccine-induced humoral responses for healthy individuals and hematological patients from these two locations (40,41). Overall, the majority of studies have shown substantially lower humoral response in hematological cancer patients compared to healthy individuals.…”
Section: Discussionmentioning
confidence: 87%
“…However, it's important to emphasize that our healthy cohort samples were collected from a different demographic location (Italy) than the patient cohort (Denmark). Although, prior studies have shown comparable vaccine-induced humoral responses for healthy individuals and hematological patients from these two locations (40,41). Overall, the majority of studies have shown substantially lower humoral response in hematological cancer patients compared to healthy individuals.…”
Section: Discussionmentioning
confidence: 87%
“…CD4+ T-helper lymphocytes (Th) support potent B-cell activation and differentiation into antibody-secreting cells and have been identified as directly controlling antibody responses and mediating an adjuvant activity ( 6 ). Recent reports have highlighted the discordance of the humoral response with T cell responses after COVID-19 vaccination in cancer patients in contrast to healthy controls, where responses are better coordinated ( 33 ). Furthermore, many studies have found that decreased magnitudes of T cell responses in cancer patients compared to healthy controls can be observed by quantification of interferon-γ (IFN-γ) using enzyme-linked immunospot (ELISPOT) assays or using flow-cytometry to detect T cell quantification assays or cytokine-producing T cells ( 34 , 35 ).…”
Section: Discussionmentioning
confidence: 99%
“…In response to the viral pandemic, several vaccines have been proposed, including novel mRNA vaccines, which have a high efficacy of over 90% [ 3 , 4 ]. To date, vaccination represents the key preventative strategy against SARS-CoV-2, but it might be associated with a suboptimal immune response in immunocompromised subjects, including cancer patients, in comparison to the general population [ 5 , 6 ]. Both B- and T-cell-mediated immune responses are elicited by vaccination and involve different mechanisms, including the production of neutralizing antibodies and the elimination of infected cells.…”
Section: Introductionmentioning
confidence: 99%